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Nanotechnology in Vaccine 
Development: A Step Forward
Adnan Nasir1
The study of nanotechnology for epicutaneous delivery of pharmaceuticals and 
vaccines is burgeoning. Topically applied nanomaterials have been shown to 
enter tape-stripped skin and reach draining lymph nodes in an inbred strain of 
mice. Nanomaterials in the form of plasmid DNA, proteins, and virus particles 
accumulate in hair follicles, diffuse via dendritic cells to draining lymph nodes, 
and elicit antigen-specific humoral and cell-mediated immunity. Topically 
immunized mice have also demonstrated resistance to infection with live virus. 
Advantages of nanotechnology include uniformity, reproducibility, and precision 
in the synthesis and manufacture of candidate compounds. Combined with novel 
pharmacokinetics and the possibility of targeted therapy, nanotechnology-based 
vaccines may prove superior to existing vaccines and have the potential to open 
therapeutic avenues for treating infectious disease and malignancy.
Journal of Investigative Dermatology (2009), 129, 1055–1059. doi:10.1038/jid.2009.63
The history of infectious disease in 
humans is a cyclical tug-of-war between 
host and parasite and host and pathogen 
(Donelson and Donelson, 2008). The 
cost to society over the course of history 
has been staggering, with epidemics 
ravaging whole populations. Over time, 
this cost has not diminished, in either 
its scope or its extent. According to the 
World Health Organization, of the top 
10 causes of death in the world, 5 are 
the result of infectious disease, nearly 
surpassing ischemic heart disease and 
cerebrovascular disease combined 
(World Health Organization, 2003) 
(Table 1). Although the impact of infec-
tious disease is universal, its effects are 
particularly acute in developing nations, 
where the heaviest burden falls on the 
poor (Table 2).
Looking beyond these mortality sta-
tistics, the five most prevalent diseases 
worldwide are infectious or parasitic. 
They strike where literacy rates are low, 
poverty is epidemic, and resources are 
scarce. They drain the reserves of affect-
ed individuals and families, and rob 
communities and nations of productive 
citizens. Beyond basic sanitation and 
infrastructure, one of the most cost-
effective ways to manage infectious 
disease is vaccination. Traditional vac-
cines have considerable disadvantages, 
and novel approaches to make vac-
cines more versatile and more effective 
are urgently needed. The ideal vaccine 
would be easy to manufacture, inexpen-
sive, readily transported, and stable in a 
broad range of ambient temperatures 
and levels of humidity. Finally, a vaccine 
should be easy to administer. Needle-
based vaccines require an infrastructure 
of sterile materials and trained person-
nel, and they generate hazardous waste 
(Glenn et al., 2000). Furthermore, they 
are painful and can meet with psycho-
logical and cultural resistance, making 
needle-free alternatives desirable. One 
advantage of epicutaneous vaccination 
is that resident antigen-presenting cells 
can induce powerful and sustained 
immune responses; in at least one study, 
these allowed for antigen dilution to 
one-fifth, potentially reducing vaccine 
cost (Nasir, 2008) and increasing vac-
cine availability (Nel et al., 2006).
Nanoparticles and nanomaterials 
with biological activity exist in nature 
(Oberdorster et al., 2005). Viruses are 
one of the more salient examples. 
Viruses can induce natural immunity 
through clinical or subclinical infec-
tion via epicutaneous, respiratory, and 
gastrointestinal routes. The induction 
of “artificial” immunity using nano-
materials is not a recent phenomenon. 
Smallpox has existed for millennia 
and has been well documented in his-
tory. Clinical examples of skin lesions 
can be identified on the mummy of 
Ramses V (Hornung, 1997). Smallpox 
descriptions taper off in late Roman and 
early Christian texts, suggesting that 
the disease was dormant for centuries 
before making a resurgence in Medieval 
Europe and then in Asia.
The earliest description of the pro-
cess of inoculating a naive individual 
with (viral) nanoparticles may have 
been given in 1549 by Wu Quan 
(Temple, 1986). It is most likely that 
therapy for smallpox was developed at 
this time, although some China scholars 
table 2. Global burden of disease
rank Disease no. infected 
(millions)
1 Malaria 800
2 Filariasis 280
3 Leishmaniasis 200
4 Schistosomiasis 200
5 Trypanosomiasis 13
From the World Health Organization, 2003.
table 1. top causes of mortality 
worldwide
rank cause % of Deaths
1 Ischemic heart disease 12.6
2 Cerebrovascular disease 9.7
3 Lower respiratory  
infection
6.8
4 HIV/AIDS 4.9
5 Chronic obstructive  
pulmonary disease
4.8
6 Diarrheal disease 3.2
7 Tuberculosis 2.7
8 Malaria 2.2
9 Cancer of trachea/
bronchus/lung
2.2
10 Road traffic accidents 2.1
From the World Health Organization, 2003.
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contend that the origins can be traced 
to the Song Dynasty (960–1279 a.d.) 
(Needham, 1999). Wu Quan described 
a powder made from the crust of small-
pox lesions that was blown into the 
nasal passages of the vaccinees. At the 
time, it was understood that inocula-
tion of live material from patients who 
had full-blown disease (Variola major) 
led to high mortality, and the procedure 
was therefore banned. Lesional crust for 
incorporation into the powder could be 
harvested only from subjects who had 
a few crusts by proxy (Variola minor). 
This practice of inoculation became 
widespread in Central Asia, South Asia, 
and Asia Minor (Wujastyk, 1995). It was 
later varied to include scarification of 
the skin and was introduced to England 
by Lady Mary Wortley Montagu in 
1717, practiced anecdotally by farmers 
and milkmaids, and subsequently per-
fected by Edward Jenner in 1796 (Bray 
and Roy, 2004).
Predecessor vaccination methods 
were cost-effective. However, as indi-
cated by the mortality due to inappro-
priate administration of vaccines (e.g., 
from Variola major), these methods were 
nonspecific and imprecise. The advent 
of nanotechnology enabled the precise 
manufacture of materials with desirable 
properties and the removal of undesir-
able features (Table 3). This selectivity, 
combined with the compactness of the 
nanoscale, allows the development of 
a wide range of useful agents. Safety 
issues notwithstanding, the potential 
for nanotechnology in vaccine devel-
opment is significant (Castanedo-
Tardan et al., 2007; Nasir, 2008; Nasir 
and Gaspari, 1996; Nel et al., 2006; 
Oberdorster et al., 2005; Warheit et al., 
2007).
The skin has both active and pas-
sive barrier defenses that retard the 
entry of pathogens. To be successful, 
nanomaterials must bypass these 
defenses. A variety of studies have 
demonstrated that nanomaterials can 
penetrate the skin. Penetration is typi-
cally through the follicular route and 
diminishes with increasing nanomate-
rial size (Mortensen et al., 2008; Vogt et 
al., 2006). Particles larger than 100 nm 
are not likely to penetrate intact skin. 
However, skin that is damaged, flexed, 
or otherwise altered may be more per-
meable to particles. Patients with atopic 
dermatitis demonstrate slightly greater 
vulnerability to cutaneous viral infec-
tions (for example, by molluscum con-
tagiosum or herpes simplex) (Bork and 
Brauninger, 1988; Erdmann et al., 2004; 
Kakourou et al., 2005; Wollenberg et 
al., 2003). Furthermore, nanomateri-
als or their vehicles may be modified to 
gain purchase on the skin or to enter via 
follicular and interfollicular routes.
In this issue, Mahe et al. (2009) 
report a mouse model for testing nano-
material penetration and immunogenic-
ity. The authors increase the potential 
for nanomaterial penetration by three 
means. First, the skin to which the anti-
gen is to be applied is tape-stripped. 
Tape-stripping not only may decrease 
barrier function but also may increase 
the expression of immunostimulatory 
cytokines and surface markers on kera-
tinocytes. Second, the mice are anes-
thetized for 1 hour to allow undisturbed 
penetration of the applied material. 
Third, the authors selected the C57BL/6 
inbred mouse strain, which has unique 
immunological (they favor a Th1 
response) and behaviorial (they tend to 
groom and barber as a form of domi-
nance) properties (Sarna et al., 2000; 
Von Stebut and Udey, 2004).
In a series of elegant experiments, 
the authors found that nanomaterials 
can penetrate tape-stripped skin. They 
used several methods to demonstrate 
penetration (Figure 1). Fluorescent 
40- and 200-nm particles called fluo-
rospheres emit a yellow–green fluores-
cence at 515 nm. In vivo confocal laser 
scanning microscopy demonstrated 
the accumulation of these particles in 
round aggregates at a depth of 80 µm, 
corresponding to the location of hair 
follicles. The initial distribution was 
compact and bright after 5 hours, but 
gradually diffused over 24 hours, sug-
gesting skin uptake. When epidermal 
cells were harvested 3 hours after appli-
cation and sorted for antigen-presenting 
cells (CD11c+, CD207+), nearly one-
third contained fluorospheres. At 4, 
24, and 48 hours after application, the 
authors harvested draining lymph nodes 
and compared them with nondraining 
lymph nodes for the presence of fluoro-
spheres. They were able to demonstrate 
accumulations as early as at 4 hours—
and a peak of 40 nm fluorospheres by 
24 hours—in draining lymph nodes, and 
there was an absence of fluorescence 
in nondraining lymph nodes. Results 
for 200-nm fluorospheres showed a 
smaller peak at 4 hours (approximately 
one-third of the 40-nm peak) and subse-
quent diminution over 24 and 48 hours. 
When CD11c+ cells were purified from 
these draining lymph nodes, they were 
found to contain fluorospheres. These 
studies suggest a rapid accumulation of 
nanoparticles in hair follicles, attach-
ment to and uptake by dendritic cells, 
and migration of fluorosphere-laden 
dendritic cells to the ipsilateral lymph 
node within 4–24 hours. The absence 
of fluorescence in nondraining nodes 
indicates a cutaneous–lymphatic route 
of migration rather than a cutaneous–
circulatory route.
Next, the authors tested the ability 
of nanoparticulate antigens to gener-
ate an immune response after topical 
application. The antigens selected were 
|Nanomaterials  can penetrate  tape-stripped  
skin effectively.
table 3. Sources of nanomaterials
anthropogenic natural Incidental engineered
Frying Volcanic ash Forest fires Carbon nanotubes
Cooking Ocean spray Plasma Quantum dots
Sandblasting Biomagnetite Meteorites Sunscreen
Mining Ferritin Mineral composites Semiconductor wires
Metalwork Virus Fullerenes
Diesel exhaust Clouds
Adapted from Oberdorster et al., 2005.
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plasmid DNA encoding ovalbumin 
(OVA), OVA protein, and OVA conju-
gated with cholera toxin. Based on my 
calculations and the current literature, 
these particles measure 20–70, 5, and 
5.5 nm, respectively (Braga and Ricci, 
2004). In these experiments, host mice 
were first intravenously administered 
4 million prelabeled naive CD8-OT1 
cells from a strain of mice with a spe-
cific immune response to peptides 
257–264 (SIINFEKL) of OVA. The cells 
lost the intensity of their label through 
cytoplasmic dilution as they underwent 
proliferation and division.
Cell-mediated responses to topi-
cal application of antigen compared 
with PBS controls were measured at 
day 4 by flow cytometry of fluorescent 
labeling for CD8+ cells in draining and 
non draining lymph nodes. The authors 
found that CD8-OT1 proliferation was 
greatest in response to OVA protein 
(83% proliferating cells in draining 
lymph nodes vs. 68% in nondraining 
lymph nodes) as compared with OVA 
plasmid DNA (21% proliferating cells 
in draining lymph nodes vs. 15% in 
nondraining lymph nodes). The efficacy 
of plasmid DNA was roughly equiva-
lent whether it was applied topically or 
injected into the tibialis anterior mus-
cle. Humoral responses were assessed 
by measuring anti-OVA IgG at day 14. 
Whereas phosphate-buffered saline 
(PBS) and OVA protein elicited negli-
gible antibody responses, OVA protein 
+ cholera toxin and OVA plasmid DNA 
elicited vigorous and nearly equivalent 
responses.
The authors subsequently determined 
whether a modified vaccinia Ankara 
(MVA) virus could penetrate skin and 
elicit immune responses. This virus par-
ticle, when modified with green fluo-
rescent protein to allow visualization, is 
approximately 290 nm in diameter. The 
authors were able to detect particles in 
situ using confocal fluorescent micros-
copy and anti-MVA antibodies, and 
they demonstrated the same intense 
follicular localization of MVA with 
diffusion and loss over 24–48 hours. 
MVA antigen could be seen in CD207+ 
cells, particularly around perifollicu-
lar dendrites. MVA antigen could also 
be detected in draining lymph nodes 
within 4 hours of topical application, 
but not in nondraining lymph nodes. 
Application of 15 × 106 particle-forming 
units (pfu) of MVA topically elicited vig-
orous production of IFN-γ by CD4 and 
CD8 cells at day 14. Similarly, a vigor-
ous elevation in neutralizing antibody 
titer was noted at day 28 in immunized 
animals compared with PBS controls.
Finally, Mahe et al. immunized 
mice topically with 5 × 106 pfu MVA 
or PBS control. Two months later, the 
mice were challenged intranasally 
with 5 ×106 pfu of live vaccinia virus. 
Animals were measured for weight 
loss as a percentage of body weight. 
Topically immunized mice lost a peak 
of 5% body weight during the study, 
whereas control mice lost nearly 11%, 
suggesting modest in vivo protection 
from live virus challenge.
The authors have nicely demonstrat-
ed in this model system that nanopar-
ticles in the 40- to 200-nm range can 
effectively penetrate tape-stripped skin 
and enter lymph nodes via dendritic 
cells and Langerhans cells. They have 
demonstrated that proteins and plas-
mid DNA can traffic to draining lymph 
nodes by the same mechanism and 
elicit cell-mediated and humoral immu-
nity. Further, the authors have shown 
that a vaccinia virus particle approxi-
mately 290 nm in size can penetrate 
tape-stripped skin and migrate within 
dendritic cells to draining lymph nodes, 
where they stimulate T-cell cytokine 
production and neutralizing antibody 
production, thereby conferring relative 
immunity against live virus challenge.
Several interesting questions remain. 
Do the applied nanomaterials local-
ize solely in hair follicles; if so, why? 
Are nanomaterials on nonfollicular skin 
groomed off or rubbed away? Or do they 
accumulate and aggregate in the follicles 
through some funnel or drain effect? Are 
there properties of the infundibulofol-
licular epithelium (for example, charge, 
pH, lipids, commensal organisms) per-
missive to nanoparticle accumulation? 
Once nanoparticles accumulate in the 
follicle, do they require a threshold 
Figure 1. tape-stripped c57BL/6 mice permit perifollicular penetration of topically applied 
nanoparticles. Particles tested include 40-nm beads, 200-nm beads, ovalbumin protein (pOVA), pOVA 
coupled to cholera toxin (pOVACT), plasmid DNA–encoding ovalbumin protein (pOVA DNA), and 
290-nm modified vaccinia Ankara virus (MVA). When applied topically, nanoparticles aggregate around 
hair follicles and disperse into the skin, where they are taken up by epidermal Langerhans cells and 
dermal dendritic cells. Skin surrounding the upper part of the hair follicle is especially rich in antigen-
presenting cells. These cells migrate to ipsilateral lymph nodes and present antigen to T cells, leading to 
T-cell proliferation and cytokine production as well as neutralizing antibody production. Mice topically 
immunized with MVA respond to live virus challenge by maintaining stable weight, whereas control 
mice lose up to 11% body weight within 1 week of live virus challenge.
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density or concentration to penetrate 
into the skin, and is this density lacking 
in interfollicular skin? Would occlusion 
enhance epicutaneous penetration, 
even in interfollicular skin? What form 
of nanoparticles do dendritic cells prefer 
for uptake: dispersed, aggregated, bulk? 
What surface properties of nano particles 
favor dendritic cell uptake? (He et al., 
2007; Ramakrishna et al., 2007). For 
example, in some models, nanoparticles 
are more readily taken up by cells if 
they are spherical rather than cylindri-
cal, whereas in other models (Gratton 
et al., 2008; Lee et al., 2007; Zhang et 
al., 2008), a cylindrical shape is favored. 
Is there some aspect of tape stripping 
that favors dendritic cell migration? Do 
keratinocytes serve as bystanders or 
costimulators in this process? (Burns et 
al. , 1999; Gaspari et al., 1998a; Gaspari 
et al., 1998b). Are there other vehicles 
that can be used to enhance the pene-
tration of nanomaterials or simulate the 
ancillary effects of tape stripping? What 
combination of adjuvants would be 
preferable for topical preparations? (He 
et al., 2007; Kenney et al., 2004; Martin 
and Gaspari, 2008; Yeh et al., 1997). 
What antigen or vehicle variables can 
be exploited to maximize cell-mediated 
responses versus humoral responses? 
Are the responses seen in this animal 
model unique to the C57BL/6 strain or 
are they generalizable? Is this method-
ology suitable for the administration of 
multiple vaccines? (Glenn et al., 2000). 
Can multiple vaccines be designed to 
have synergistic effects?
Pathogens have developed a num-
ber of strategies to evade the immune 
system, from hiding intracellularly to 
inducing tolerance, to shedding surface 
markers, to serially switching dominant 
antigenic epitopes (Berriman et al., 
2005; Donelson and Donelson, 2008; 
El-Sayed et al., 2005; Nasir et al., 1987; 
Von Stebut and Udey, 2004). Some 
of these mechanisms are also used by 
tumors to evade immune surveillance. 
The road to vaccine design and devel-
opment is long, tangled, and unpre-
dictable. Countless investigator years 
and solid supportive preliminary data 
have led to one of the largest and cost-
liest HIV vaccine clinical trials in his-
tory. Yet the result—increased infection 
rates in treated individuals—was both 
puzzling and profoundly disappointing. 
The complexity of the population being 
studied, their prior history of non-HIV 
viral infections, and difficulty in reach-
ing the necessary strength of humoral 
and cell-mediated arms of immunity all 
likely contributed to the failure (Cohen, 
2007; Sekaly, 2008). With the advent 
of nanotechnology, tools are becoming 
available to develop the next generation 
of vaccines, featuring easy application, 
transportability, stability, compact size, 
specific targeting, and enhanced effec-
tiveness. The results reported by Mahe 
and co-workers represent a notable step 
in that direction.
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Targeting Apoptosis Defects  
in Cutaneous T-Cell Lymphoma
E. Contassot1 and Lars E. French1
Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin’s lymphomas character-
ized by the clonal proliferation of skin-invasive mature T lymphocytes. Because of 
their low proliferative potential, the accumulation of clonal T cells is considered to 
be potentially due to their inability to undergo Fas-mediated apoptosis, a crucial 
process involved in T-cell homeostasis. Several reports have indicated a decrease 
in or absence of Fas expression in tumor cells in significant proportions of CTCL 
patients, whether or not associated with overexpression of apoptosis inhibitors. In 
this issue, Wu et al. confirm the impaired expression of Fas in CTCL cells. Moreover, 
they show that CTCL cells genetically engineered to re-express Fas acquire a sen-
sitivity to FasL-induced apoptosis, opening new avenues for therapeutic interven-
tion strategies in CTCL.
Journal of Investigative Dermatology (2009), 129, 1059–1061. doi:10.1038/jid.2009.14
Mycosis fungoides (MF), the most com-
mon type of cutaneous T-cell lymphoma 
(CTCL), and its leukemic variant, Sézary 
syndrome (SzS), are mature T-cell neo-
plasms characterized by the clonal pro-
liferation of skin-invasive T lymphocytes 
that have the phenotype of mature help-
er T cells. Because of the low replicative 
potential of CTCL cells, it is proposed 
that their accumulation may, to some 
extent, be the result of defective regula-
tion of T-cell apoptosis.
Apoptosis can be triggered by a series 
of stimuli, among which are signals 
transmitted by a family of cell-surface 
receptors—called death receptors—that 
belong to the tumor necrosis factor–
receptor family. Six death receptors are 
known—Fas (CD95, Apo-1), TRAIL-
receptor 1 (DR4), 2 (DR5, Apo-2), tumor 
necrosis factor–receptor 1, TRAMP (DR3, 
WSL-1, Apo-3), and DR6—and all con-
tain a cytoplasmic sequence called the 
“death domain” that couples the death 
receptor to downstream caspases, the 
activation of which leads to apoptosis.
The acquisition of resistance to apop-
tosis as a mechanism involved in tum-
origenesis is well documented. In sev-
eral tumor types, a decrease in or loss 
of cell-surface Fas expression compared 
with that observed in nontumor cells 
of the same lineage has been report-
ed. Likewise, mutations in the DNA 
sequence of death receptors such as Fas, 
DR4, and DR5 have been reported in sev-
eral human cancer types. Furthermore, 
in both mice and humans, Fas gene 
mutations leading to defective Fas/FasL 
signaling have been shown to result in 
lymphoproliferative disorders as a con-
sequence of lymphocyte accumulation 
(Rieux-Laucat et al., 1995). Resistance 
to apoptosis can also occur as a con-
sequence of the aberrant expression of 
intracellular apoptosis inhibitors in tumor 
cells, as reported in many cancer types. 
Among them is the FLICE-inhibitory 
protein (cFLIP), which is an intracellular 
protein that is highly homologous to cas-
pases 8 and 10 and is able to block the 
autoproteolytic cleavage of caspase-8 
that is normally induced upon trigger-
ing Fas-mediated apoptosis. An overex-
pression of cFLIP associated with a high 
expression of Fas has been reported in 
FasL-resistant Hodgkin’s/Reed–Sternberg 
cells, the malignant cells of Hodgkin’s 
lymphoma (Dutton et al., 2004). Similar 
observations have since been reported 
for non-Hodgkin’s lymphoma and sev-
eral other types of cancer. The relevance 
of cFLIP overexpression, and indirectly 
that of death receptor-mediated apop-
tosis in the pathogenesis of lymphoma, 
is supported by mouse models of lym-
phoma engineered to overexpress cFLIP 
in which tumor progression is enhanced 
(Djerbi et al., 1999).
Appropriate Fas-mediated cell death 
is essential in the control of lympho-
cyte homeostasis. Elimination of T cells 
after encountering a specific antigen 
or superantigen normally proceeds via 
activation-induced cell death (AICD), a 
process that is dependent on activation 
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